Nat Commun:SWI/SNF复合物的具体组成在前列腺癌谱系可塑性中的作用

2020-11-22 AlexYang MedSci原创

晚期前列腺癌最初对激素治疗有响应,但最终会产生耐药性,从而需要更有效的治疗方法。研究人员在这些患者的10%-20%的比例中观察到的耐药性机制之一是谱系可塑性,表现为部分或完全的小细胞或神经内分泌前列腺

晚期前列腺癌最初对激素治疗有响应,但最终会产生耐药性,从而需要更有效的治疗方法。研究人员在这些患者的10%-20%的比例中观察到的耐药性机制之一是谱系可塑性,表现为部分或完全的小细胞或神经内分泌前列腺癌(NEPC)表型。

最近,有研究人员调查了哺乳动物SWI/SNF(mSWI/SNF)染色质重塑复合物在NEPC中的作用。研究人员使用了大型患者数据集,患者来源的器官和癌症细胞系,确定了在NEPC中失调的mSWI/SNF亚基,并阐释了SMARCA4(BRG1)的过表达与侵袭性疾病相关。研究人员还表明,与前列腺癌相比,SWI/SNF复合物在NEPC中与不同的谱系特异性因子相互作用。

CPRC-NE中SWI SNF亚单元异常调节

这些数据指出了mSWI/SNF复合物在治疗相关谱系可塑性中的作用,这也可能与其他实体瘤相关。

原始出处:

Joanna Cyrta, Anke Augspach, Maria Rosaria De Filippo et al. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat Commun. Nov 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910661, encodeId=b12c19106617a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Mon Feb 15 03:10:27 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087827, encodeId=c189208e8270f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 28 01:10:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884804, encodeId=c58f1884804c0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 22 22:10:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040892, encodeId=7b9c1040892e6, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 22 18:10:27 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901187, encodeId=7a8390118e09, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Nov 22 15:39:51 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910661, encodeId=b12c19106617a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Mon Feb 15 03:10:27 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087827, encodeId=c189208e8270f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 28 01:10:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884804, encodeId=c58f1884804c0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 22 22:10:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040892, encodeId=7b9c1040892e6, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 22 18:10:27 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901187, encodeId=7a8390118e09, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Nov 22 15:39:51 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2021-01-28 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1910661, encodeId=b12c19106617a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Mon Feb 15 03:10:27 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087827, encodeId=c189208e8270f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 28 01:10:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884804, encodeId=c58f1884804c0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 22 22:10:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040892, encodeId=7b9c1040892e6, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 22 18:10:27 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901187, encodeId=7a8390118e09, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Nov 22 15:39:51 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2021-03-22 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1910661, encodeId=b12c19106617a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Mon Feb 15 03:10:27 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087827, encodeId=c189208e8270f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 28 01:10:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884804, encodeId=c58f1884804c0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 22 22:10:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040892, encodeId=7b9c1040892e6, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 22 18:10:27 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901187, encodeId=7a8390118e09, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Nov 22 15:39:51 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2020-11-22 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1910661, encodeId=b12c19106617a, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Mon Feb 15 03:10:27 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087827, encodeId=c189208e8270f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jan 28 01:10:27 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884804, encodeId=c58f1884804c0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 22 22:10:27 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040892, encodeId=7b9c1040892e6, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Nov 22 18:10:27 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901187, encodeId=7a8390118e09, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Nov 22 15:39:51 CST 2020, time=2020-11-22, status=1, ipAttribution=)]
    2020-11-22 ms3000000449926787

    学习学习

    0

相关资讯

Eur Urol:紫杉烷抑制CXCR2/BCL-2途径能够使前列腺癌对铂类治疗敏感

在转移去势抵抗性前列腺癌(mCRPC)患者中,紫杉烷类药物是最活跃的化疗药物;然而,耐药性总是发生,是一个重要的临床挑战。紫杉烷类-铂类联合用药在部分患者中显示出临床益处,但其机理基础和生物标志物仍然

Cell Death & Disease:MiRNA-671-5p通过靶向NFIA/CRYAB途径促进前列腺癌的发展和转移

前列腺癌(PCa)是男性恶性肿瘤致死的第二位死因,转移是PCa患者死亡的主要原因。微RNAs(miRNAs)在肿瘤的发展和转移中起着重要的调控作用。

Eur Urol:多种组织生物标志物可独立和附加地预测前列腺癌病理结果

区分慢性前列腺癌和侵袭性前列腺癌仍然是前列腺癌治疗决策的一个关键挑战。越来越多的生物标志物现在可以帮助解决上述挑战,但这些标记很少在同一患者中一起检查,从而确定它们潜在的附加价值。

Prostate:石榴果提取物对积极监测局部前列腺癌男性的影响研究

积极监测(AS)的低风险前列腺癌(PCa)的男性有可能受益于干预策略,以减缓或阻止疾病进展和正式治疗的需要。石榴及其提取物在细胞系和动物模型中表现出抗增殖和促凋亡作用,但其对人类前列腺癌的影响仍不清楚

J Cell Mol Med:Sirtuin 5能够调控前列腺癌细胞的增殖、侵袭和迁移

Sirtuin 5(SIRT5)是一种NAD+依赖性的Ⅲ类蛋白去乙酰化酶,其在前列腺癌中的作用尚未见报道。

PARP抑制剂Lynparza在欧洲获得重大成功!同时获批治疗卵巢癌和前列腺癌

阿斯利康和MSD的免疫疗法PARP抑制剂Lynparza(olaparib)在欧盟获得了两项新的批准。